Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 5.03M | $150.0M | 9.07% | +465.6K | 2026-06-30 |
| TRV GP IV, LLC | 4.47M | $133.0M | 8.06% | -- | 2026-06-30 |
| ARCH Venture Management, LLC | 4.12M | $122.0M | 7.42% | -- | 2026-06-30 |
| Deep Track Capital, LP | 3.73M | $111.0M | 6.72% | +255.0K | 2026-06-30 |
| BlackRock, Inc. | 3.50M | $104.0M | 6.31% | +932.4K | 2026-06-30 |
| Jupiter Topco LLC | 3.41M | $101.0M | 6.14% | -- | 2026-06-30 |
| T. Rowe Price Investment Management, Inc. | 2.60M | $77.0M | 4.69% | -- | 2026-06-30 |
| Logos Global Management LP | 1.94M | $57.0M | 3.49% | +700.0K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.78M | $53.0M | 3.20% | +342.6K | 2026-06-30 |
| a16z Capital Management, L.L.C. | 1.70M | $50.0M | 3.07% | -- | 2026-06-30 |
